300 related articles for article (PubMed ID: 34388483)
21. Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position.
Tolan D; Gandin V; Morrison L; El-Nahas A; Marzano C; Montagner D; Erxleben A
Sci Rep; 2016 Jul; 6():29367. PubMed ID: 27404565
[TBL] [Abstract][Full Text] [Related]
22. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
23. Platinum(IV) complexes conjugated with chalcone analogs as dual targeting anticancer agents: In vitro and in vivo studies.
Huang X; Liu Z; Wang M; Yin X; Wang Y; Dai L; Wang H
Bioorg Chem; 2020 Dec; 105():104430. PubMed ID: 33171407
[TBL] [Abstract][Full Text] [Related]
24. Platinum(IV) complexes conjugated with phenstatin analogue as inhibitors of microtubule polymerization and reverser of multidrug resistance.
Huang X; Huang R; Gou S; Wang Z; Liao Z; Wang H
Bioorg Med Chem; 2017 Sep; 25(17):4686-4700. PubMed ID: 28728896
[TBL] [Abstract][Full Text] [Related]
25. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
Chen H; Wang X; Gou S
J Inorg Biochem; 2019 Apr; 193():133-142. PubMed ID: 30731264
[TBL] [Abstract][Full Text] [Related]
26. NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway.
Chen TJ; Zhou YF; Ning JJ; Yang T; Ren H; Li Y; Zhang S; Chen MW
Cell Physiol Biochem; 2015; 36(3):893-906. PubMed ID: 26065336
[TBL] [Abstract][Full Text] [Related]
27. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
28. A novel coordination complex of platinum (PT) induces cell death in colorectal cancer by altering redox balance and modulating MAPK pathway.
Al-Khayal K; Vaali-Mohammed MA; Elwatidy M; Bin Traiki T; Al-Obeed O; Azam M; Khan Z; Abdulla M; Ahmad R
BMC Cancer; 2020 Jul; 20(1):685. PubMed ID: 32703189
[TBL] [Abstract][Full Text] [Related]
29. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
Wang Z; Xu Z; Zhu G
Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
[TBL] [Abstract][Full Text] [Related]
30. Blocking xCT and PI3K/Akt pathway synergized with DNA damage of Riluzole-Pt(IV) prodrugs for cancer treatment.
Li Z; Qiao X; Liu XM; Shi SH; Qiao X; Xu JY
Eur J Med Chem; 2023 Mar; 250():115233. PubMed ID: 36863224
[TBL] [Abstract][Full Text] [Related]
31. Anticancer Melatplatin Prodrugs: High Effect and Low Toxicity, MT1-ER-Target and Immune Response
Song XQ; Liu RP; Wang SQ; Li Z; Ma ZY; Zhang R; Xie CZ; Qiao X; Xu JY
J Med Chem; 2020 Jun; 63(11):6096-6106. PubMed ID: 32401032
[TBL] [Abstract][Full Text] [Related]
32. CAIXplatins: Highly Potent Platinum(IV) Prodrugs Selective Against Carbonic Anhydrase IX for the Treatment of Hypoxic Tumors.
Cao Q; Zhou DJ; Pan ZY; Yang GG; Zhang H; Ji LN; Mao ZW
Angew Chem Int Ed Engl; 2020 Oct; 59(42):18556-18562. PubMed ID: 32557982
[TBL] [Abstract][Full Text] [Related]
33. Single-Cell Chemistry of Photoactivatable Platinum Anticancer Complexes.
Bolitho EM; Sanchez-Cano C; Shi H; Quinn PD; Harkiolaki M; Imberti C; Sadler PJ
J Am Chem Soc; 2021 Dec; 143(48):20224-20240. PubMed ID: 34808054
[TBL] [Abstract][Full Text] [Related]
34. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt
Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G
Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087
[TBL] [Abstract][Full Text] [Related]
35. Luminescent Pt
Lázaro A; Balcells C; Quirante J; Badia J; Baldomà L; Ward JS; Rissanen K; Font-Bardia M; Rodríguez L; Crespo M; Cascante M
Chemistry; 2020 Feb; 26(9):1947-1952. PubMed ID: 31909511
[TBL] [Abstract][Full Text] [Related]
36. Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity.
Liu XM; Li Z; Xie XR; Wang JQ; Qiao X; Qiao X; Xie CZ; Xu JY
J Med Chem; 2023 Feb; 66(3):1852-1872. PubMed ID: 36715603
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and Cytotoxic Study of a Platinum(IV) Anticancer Prodrug with Selectivity toward Luteinizing Hormone-Releasing Hormone (LHRH) Receptor-Positive Cancer Cells.
Yao H; Xu Z; Li C; Tse MK; Tong Z; Zhu G
Inorg Chem; 2019 Aug; 58(16):11076-11084. PubMed ID: 31393117
[TBL] [Abstract][Full Text] [Related]
38. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
Gibson D
J Inorg Biochem; 2021 Apr; 217():111353. PubMed ID: 33477089
[TBL] [Abstract][Full Text] [Related]
39. Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance.
Wang M; Li G; Jiang G; Cai J; Liu Z; Huang R; Huang X; Wang H
J Med Chem; 2024 Apr; 67(8):6218-6237. PubMed ID: 38573870
[TBL] [Abstract][Full Text] [Related]
40. Heterodinuclear Pt(iv)-Ru(ii) anticancer prodrugs to combat both drug resistance and tumor metastasis.
Ma L; Ma R; Wang Z; Yiu SM; Zhu G
Chem Commun (Camb); 2016 Sep; 52(71):10735-8. PubMed ID: 27506281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
